Fludeoxyglucose (18F)

Generic Name: Fludeoxyglucose (18F)

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₁FO_₅

CAS Number: 63503-12-8

Unique Ingredient Identifier: 0Z5B2CJX4D

Background: Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2-[18F]fluoro-D-g1ucose, which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET). It is administered by intravenous injection.

Indication: The uptake of 18F-FDG by tissues is a marker for the tissue uptake of glucose, which in turn is closely correlated with certain types of tissue metabolism.
...

Associated Conditions: Cancer, Coronary Artery Disease (CAD), Epileptic seizure, Left Ventricular Dysfunction

Associated Therapies: -

Clinical Trials

Pilot Breast-Dedicated PET Camera With 1 Millimeter Spatial Resolution

Early Phase 1

Not yet recruiting

Conditions: Breast Cancer

Interventions: Drug: 18F-FDG
Device: Breast-dedicated PET camera

First Posted Date: 2019-07-12

Last Posted Date: 2024-06-12

Lead Sponsor: Stanford University

Target Recruit Count: 20

Registration Number: NCT04016818

Locations: 🇺🇸
Stanford University, Stanford, California, United States

18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules

Phase 2

Recruiting

Conditions: Multiple Pulmonary Nodules
Pulmonary Nodule
Current Smoker
Cigarette Smoker
Former Smoker

Interventions: Procedure: Computed Tomography
Drug: Fludeoxyglucose F-18
Drug: Fluorine F 18 L-glutamate Derivative BAY94-9392
Procedure: Positron Emission Tomography

First Posted Date: 2019-01-31

Last Posted Date: 2024-03-05

Lead Sponsor: Andrei Iagaru

Target Recruit Count: 50

Registration Number: NCT03824535

Locations: 🇺🇸
Stanford Cancer Institute Palo Alto, Palo Alto, California, United States

Arterial Imaging of Inflammation and Resolution After Endovascular Surgery

Phase 1

Completed

Conditions: Iliac Artery Disease
Claudication, Intermittent
PAD
Peripheral Arterial Disease
Claudication
SFA - Superficial Femoral Artery Stenosis
Vascular Calcification

Interventions: Drug: 18F-FDG

First Posted Date: 2018-07-18

Last Posted Date: 2020-11-30

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 9

Registration Number: NCT03590769

Locations: 🇺🇸
UCSF, San Francisco, California, United States
🇺🇸
San Francisco General Hospital, San Francisco, California, United States

Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation Therapy

Phase 1

Completed

Conditions: Stage II Lung Cancer
Stage IIB Non-Small Cell Lung Carcinoma AJCC v7
Stage I Non-Small Cell Lung Cancer AJCC v7
Stage IA Non-Small Cell Lung Carcinoma AJCC v7
Stage IB Non-Small Cell Lung Carcinoma AJCC v7
Stage IIA Non-Small Cell Lung Carcinoma AJCC v7
Stage I Lung Cancer
Stage II Non-Small Cell Lung Cancer AJCC v7

Interventions: Drug: Fludeoxyglucose F-18
Procedure: Positron Emission Tomography (PET)
Radiation: Stereotactic Body Radiation Therapy (SBRT)

First Posted Date: 2018-04-11

Last Posted Date: 2023-10-18

Lead Sponsor: Emory University

Target Recruit Count: 19

Registration Number: NCT03493789

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

First Posted Date: 2018-02-14

Last Posted Date: 2023-09-13

Lead Sponsor: Mayo Clinic

Target Recruit Count: 39

Registration Number: NCT03432741

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Detection of Functioning Pituitary Microadenoma: PET/MRI Versus PET/CT

Phase 1

Conditions: Pituitary Adenoma

Interventions: Drug: 18F-FDG

First Posted Date: 2018-01-19

Last Posted Date: 2018-01-19

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 100

Registration Number: NCT03404414

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

Phase 2

Conditions: Prostatic Cancer
Prostate Cancer
Prostate Neoplasms
Cancer Of Prostate
Metastatic Prostate Cancer

Interventions: Drug: 18F-DCFPyL
Drug: PSMA-11
Drug: 18F-FDG

First Posted Date: 2017-06-09

Last Posted Date: 2024-12-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 330

Registration Number: NCT03181867

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Prostate Cancer
Prostatic Cancer
Prostate Neoplasms
Prostatic Neoplasms
Prostate Cancer

Interventions: Drug: 18F-NaF
Drug: 18F-DCFPyL
Drug: 18F-FDG

First Posted Date: 2017-06-02

Last Posted Date: 2024-11-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 96

Registration Number: NCT03173924

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Hyperpolarized 13C MR Imaging of Lactate in Patients With Locally Advanced Cervical Cancer (LACC) Cervical Cancer

Phase 1

Terminated

Conditions: Uterine Cervical Neoplasms

Interventions: Drug: Hyperpolarized 13C-Pyruvate
Drug: 18F-FDG

First Posted Date: 2017-04-26

Last Posted Date: 2022-09-22

Lead Sponsor: Sunnybrook Health Sciences Centre

Target Recruit Count: 4

Registration Number: NCT03129776

Locations: 🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

18F-FLT PET Imaging in Patients With Advanced Melanoma

Phase 1

Terminated

Conditions: Melanoma

Interventions: Drug: fludeoxyglucose F 18
Device: Positron emission tomography-computed tomography
Drug: 18F-fluorothymidine
Device: Positron emission tomography-magnetic resonance imaging

First Posted Date: 2016-09-07

Last Posted Date: 2019-07-17

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 4

Registration Number: NCT02891616

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy